title: Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management.
abstract: Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pathomorphologically and immunohistochemically detectable lesion which biological significance and clinical relevance is unknown. Areas covered: We investigate methods of STIC diagnostics and we present an overview of recent studies and available knowledge on surgical management, adjuvant chemotherapy and subsequent follow-up procedure in women with an isolated STIC. Expert commentary: Patients found to have an incidental STIC lesion should be referred for screening of BRCA1/2 mutation. In absence of an invasive disease, follow-up of patient remains a reasonable choice. A rational scheme should include check-ups every 6 months consisting of gynecological examinations, CA 125 and/or HE4 and pelvic ultrasound examination by an expert sonographer.
authors.affiliation: a Department of Gynecology and Obstetrics , University Hospital Brno, Masaryk University, Faculty of Medicine , Brno , Czech Republic.
authors.forename: Vit
authors.initials: V
authors.lastname: Weinberger
authors.affiliation: b Department of Hematology and Oncology , University Hospital Brno, Masaryk University, Faculty of Medicine , Brno , Czech Republic.
authors.forename: Marketa
authors.initials: M
authors.lastname: Bednarikova
authors.affiliation: c Gynecological Oncology Center, Department of Obstetrics and Gynecology , Charles University in Prague - First Faculty of Medicine , Prague 2 , Czech Republic.
authors.forename: David
authors.initials: D
authors.lastname: Cibula
authors.affiliation: c Gynecological Oncology Center, Department of Obstetrics and Gynecology , Charles University in Prague - First Faculty of Medicine , Prague 2 , Czech Republic.
authors.forename: Michal
authors.initials: M
authors.lastname: Zikan
mesh_terms: D000818:Animals; D019313:BRCA1 Protein / Q000235:genetics; D024682:BRCA2 Protein / Q000235:genetics; D002278:Carcinoma in Situ / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D005185:Fallopian Tube Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D015994:Incidence; D009154:Mutation; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*
chemical_list: D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human
keywords: BRCA mutation; fallopian tube; ovarian carcinoma; risk reducingsalpingo-oophorectomy; serous tubal intraepithelial carcinoma